LearnGlossaryMarketStocksSuperinvestorsSign in

KYNB

Kyntra Bio, Inc.

Healthcare · $28M market cap

Verdict

We can't put a fair value on KYNB right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-4.3% a year✗
Sales growth-3.5% a year✗
Free cash flow growth22.2% a year✓
Return on invested capital-63.0%✗

Follow KYNB

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 6, 2026: no open-market purchases and 2 other filings (stock awards, tax withholding and similar). Why purchases matter

Other filings

DeLucia David

Chief Financial Officer · 2026-09-06

Tax withholding

$188

Wettig Thane

CEO · 2026-09-06

Tax withholding

$2K

About Kyntra Bio, Inc.

Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works